Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medicenna Therapeutics Corp. has unveiled promising preclinical data from its BiSKIT and IL-2 Super Agonist programs, showcasing potential breakthroughs in cancer treatment. Their novel therapies, MDNA113 and MDNA11, have demonstrated significant tumor regression and survival benefits in aggressive cancer models, promising hope for millions affected by tumors worldwide.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.